27 min ago
Research and Markets: Chinese Adalimumab Market Report - Forecasts to 2018
Adalimumab is a TNF inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA.
Trending on the Topix Network
Mon Mar 10, 2014
Abbott Laboratories Coverage Initiated by Analysts at Singular Research
The firm set a "sell" rating and a $30.00 price target on the stock. Singular Research's target price points to a potential downside of 24.18% from the stock's previous close.
Wed Mar 05, 2014
The Motley Fool
Better Dividend: Abbott Laboratories vs. Medtronic, Inc.
Each stock also offers a reliable dividend, with both Medtronic and Abbott belonging to the S&P 500's Dividend Aristocrats, the group of companies that have raised their dividends annually for at least the past 25 years.
Courthouse News Service
Officer Says Antibiotic Biaxin Made Him Crazy
A generic version of the antibiotic Biaxin made a police officer psychotic, believe himself a prophet, and open fire on firefighters trying to help him because he thought they were demons, the officer claims in court.
Mon Mar 03, 2014
UnitedHealth joint venture picks Medtronic for big stent contract
Med-tech giants Medtronic Inc. and Abbott Laboratories won the first round of medical-device contracts awarded by SharedClarity , a joint venture that covers roughly 135 U.S. hospitals.
Thu Feb 27, 2014
Sumitomo Chemical Company, Ltd. Announces Retirement of Mike Donaldson
President and CEO of Valent U.S.A. Corporation, Valent BioSciences and Pace International Retires After 35 Years of Service to the Industry; Successors Announced )--Sumitomo Chemical Company, Limited , Tokyo, Japan, announced that Michael Donaldson, president and CEO of Valent U.S.A. Corporation , Valent BioSciences Corporation , and Pace ... (more)
Wed Feb 26, 2014
The Motley Fool
Can Abbott Laboratories Beat Baxter International and Edwards Lifesciences in 2014?
However, Abbott Laboratories was not the only Healthcare Equipment stock to be handsomely beaten by the S&P 500.
Mon Feb 24, 2014
Pensions & Investments
Abbott Laboratories eyes $300 million pension contribution
Abbott Laboratories plans to contribute about $400 million to its post-retirement plans in 2014, of which about $300 million will go to its main domestic pension fund.
Fri Feb 21, 2014
Abbott Laboratories - 10-K - Management's Discussion and Analysis of...
Financial Review Abbott's revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements.
The Motley Fool
Can Boston Scientific Outperform the Index in 2014?
Indeed, the medical devices manufacturer has delivered a profit in only three of the last five years.
Wed Feb 19, 2014
Abbott Labs Should Be In Your Dividend Growth Portfolio
Dividend growth investors are a group of individuals that fill their portfolios with stocks that have a strong history of increasing their dividends every year.
Tue Feb 11, 2014
Global IVD products market: 4% CAGR growth expected between 2012-2016
One of the key factors contributing to this market growth is the significant growth of the IVD market in emerging countries.
Mon Feb 10, 2014
Abbott Labs Has A Safe Dividend Yield
The last time I wrote about Abbott Laboratories I stated, "I'm going to avoid pulling the trigger here and wait to see how they report."
Nevada Attorney General Reverses, Seeks to Withdraw State's Defense of Gay Marriage Ban
Nevada Attorney General Catherine Corte Masto, who in January compared gay marriage to bigamy and incest in a brief defending the state's ban and shortly thereafter said she would reconsider the brief in light of the 9th Circuit's opinion in SmithKline Beechum Corp. v.
Bioactives American brings first GRAS-affirmed salacia oblonga extract to market
Bioactives American Corporation has brought to market what the company calls the first GRAS version of a salacia oblonga ingredient for blood sugar management.